@dansfera: The ultimate regulatory tightrope walk! 🤯 Witness the fascinating case of Biogen's Alzheimer's treatment, Aduhelm. An expert advisory committee (ADCOM) unanimously signaled *no* due to controversial efficacy, but the FDA chose the path of accelerated approval anyway. This historic vote, 10-to-1 against, proves that an agency's internal panel recommendation isn't always the final destination for a first-in-class biologic. Talk about a precedent-setting moment! #FDA #ADCOM #Alzheimers #DrugApproval

dansfera

Open In TikTok:

Region: US

Friday 09 January 2026 16:35:32 GMT